Advertisement
Advertisement
U.S. markets open in 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIOW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.0232+0.0062 (+36.47%)
At close: 04:56PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells

    Phio Pharmaceuticals Corp (NASDAQ: PHIO) presented new preclinical data showing that silencing BRD4 with PH-894 can improve the quality and potency of HER2-targeted CAR-T cells in a CAR-T expansion model. These new data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting. Related: Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation. Results showed that PH-894 reduced the expansion-associated production of BRD4 and BRD4-reg

  • PR Newswire

    Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new preclinical data showing that silencing BRD4 with PH-894, a self-delivering RNAi INTASYL compound, can be used to improve the characteristics of CAR-T cell products during the activation and expansion phases of the cell manufacturing process. These new data will be presen

  • PR Newswire

    Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.

Advertisement
Advertisement